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CHAPTER 1: INTRODUCTION
Concussion, a type of brain injury, has risen to the forefront of sports medicine
research. An estimated 1.6 to 3.8 million sport and recreation concussion-related injuries
occur annually in the United States1. This complex and often controversial injury has
generated significant discourse regarding player safety and the rules by which sports are
regulated. The National Football League and National Collegiate Athletics Association
(NCAA) have attempted to protect players by implementing rule changes (e.g., penalties
for targeting, helmet to helmet contact, etc.) and a concussion protocol, in which athletes
are removed from play and evaluated following a suspected concussion. Since 2012 the
NFL Foundation has dedicated nearly $500 million toward safety initiatives and research2,
and the NCAA - Department of Defense (NCAA-DOD) Grand Alliance Concussion
Assessment, Research and Education (CARE) Consortium has allocated over $50 million
to produce research on concussion risks, treatment and management by studying how
concussions evolve over time3, 4. Collectively, these events reflect the immediate need to
increase our awareness and understanding of the factors that influence concussion.
Concussion is the result of a biomechanical force to the head or body resulting in
neurometabolic impairments which manifest in varying degrees of symptom severity. The
most common symptoms following concussion are balance disturbances, headache,
dizziness, fatigue, sleep disturbances, light and/or sound sensitivity, cognitive impairment,
and mood disturbances5. Concussion has been called a transient injury (i.e., short-lived)
because most clinical symptoms typically resolve within a month of injury5. However, this
1

view of concussion has undergone scrutiny as evidence accumulates suggesting deficits
persist beyond clinical recovery6-14. These deficits are thought to reflect sub-clinical
metabolic impairments which may increase the probability of subsequent re-injury
following early RTP prior to complete metabolic recovery or permanent change in
neurologic function which may lower the physiological threshold for concussive injuries1523

. Accordingly, current consensus guidelines call for the identification of factors that may

increase risk for concussion and negatively influence recovery to better inform
management of concussion and maximize athlete health and safety24, 25.
Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (ADHD), a common neurodevelopmental
disorder, is reported to be prevalent in up 10% of college athletes26,

27

. Due to the

heterogeneity of symptoms, an unitary pathology of ADHD remains unclear, however
ADHD is believed to reflect structural, functional, and bioenergetics impairments, along
with compensatory alterations28. ADHD is predominantly characterized by age or
developmentally inappropriate degrees of inattention, hyperactivity, impulsivity, and risk
taking behaviors29. These behavioral characteristics may contribute to the increased
prevalence of negative outcomes such as anxiety or depression30-39, social impairments40,
41

, academic difficulty42, poor vocational performance43, vehicular accidents44,

45

, and

bodily injuries46 consistently observed in ADHD.
ADHD and Concussion
Research is beginning to reveal significant associations between concussion and
ADHD. Recent evidence suggests athletes with ADHD are more likely to have greater
history of single and multiple concussions, yet the literature regarding recovery remains
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unclear 25, 26, 47-51. However, the degree to which the individual and combined influences of
ADHD and concussion history contribute to the likelihood of future concussions remains
unknown.
Accumulating evidence suggests ADHD may negatively influence concussion
recovery. A meta-analysis by Biederman et al.52 suggests that athletes with ADHD have
greater symptom burden following concussion, which is consistent with other reports53.
While greater symptomology does not necessarily result in prolonged recovery, greater
initial symptoms is considered the strongest risk factor for slower recovery24. Interestingly
however, athletes with ADHD without a history of concussion reported concussion-like
symptoms at baseline such as: “problems learning”, “emotional lability”, “difficulty
concentrating”, and “difficulty remembering”50,

54-56

. These self-report measures are

subjective and therefore subject to interpretation bias, however objective computerized
neurocognitive testing (CNT) consistently reveals pronounced impairments in verbal
memory, visual memory, visual motor speed, reaction time, and response inhibition among
athletes with ADHD50,

57-61

. These findings provide evidence suggesting antecedent

ADHD, absent a history of concussion, mimics impairments induced by concussion. Thus,
given the overlap in impairments the management of concussion may be more complicated
in this population.
Stimulant Medications
Stimulant medications are the front-line treatment for ADHD and may further
compound the management of concussion in athletes with ADHD62-64. These medications
consistently demonstrate an ability to enhance executive functions (i.e., working memory,
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inhibition, attentional focus) on neurocognitive test performance59, 63, 65-68, and functional
outcomes of daily activities in both individuals with ADHD and healthy controls65, 69-73.
Purpose
Athletes with ADHD may be more vulnerable for incurring concussion due to
behavioral or physiological impairments. Furthermore, these pre-existing features may
negatively influence symptom severity and duration following concussion. Therefore, the
purposes of this investigation are 1) to determine whether athletes with ADHD have greater
likelihood of incurring a concussion than athletes without ADHD, and 2) to investigate
whether pre-existing ADHD symptoms result in greater symptoms and delayed recovery
following concussion.
Rationale
Expanding our understanding of the relationships between concussion and ADHD
has important clinical and scientific implications. If ADHD is an antecedent risk factor
for sustaining a first concussion, then it becomes vital to closely monitor these athletes
and begin to develop prevention strategies. Additionally, if ADHD with concussion
history further increases risk for future concussion, we can better identify athletes at
greatest risk for injury. Furthermore, this knowledge may lead to early prevention
strategies or the identification of ADHD specific characteristics that result in increased
risk for concussion. Finally, if ADHD is found to complicate recovery, clarifying this
relationship while considering medication status may lead to a more robust understanding
of the difficulties in the management of concussion in athletes with ADHD.
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CHAPTER 2: REVIEW OF THE LITERATURE
To better understand why concussion may be more prevalent and more severe in
athletes with ADHD, it is necessary to review existing literature on concussion and ADHD
to establish the theoretical framework on which this investigation is based. First, we will
provide an overview of concussion including the prevalence, definition and diagnosis,
injury biomechanics, pathophysiology, risk factors, signs and symptoms, and management.
Next, an analysis of ADHD including prevalence, definition and diagnosis,
pathophysiology and impairments, and management will be discussed to provide a
framework for understanding this unique population. Lastly, existing research regarding
the complex relationship between concussion and ADHD symptoms, incidence, and
recovery will be examined justify the proposed investigations.
Concussion
Prevalence
The Centers for Disease Control and Prevention estimate up to 3.8 million
concussions occur annually in sport and recreational activities74. However, surveillance
methods likely underestimate actual prevalence as most are based on emergency
department visits and do not account for concussions treated elsewhere74. Additional injury
reports created by team medical personnel may not always account for concussions
occurring outside of school-based sports75. Furthermore, athletes may fail to report
concussions because they did not think the symptoms were severe enough20, 76, or they did
not want to be removed from play77. Collectively, the prevalence of concussion likely
5

exceeds current estimates further emphasizing the need to increase our knowledge of
factors that may predispose athletes for concussion.
Definition and Diagnosis
The most recent definition of concussion is “… a complex pathophysiological
process affecting the brain, induced by traumatic biomechanical forces5.” The consensus
further identifies common clinical, pathological, and biomechanical concepts useful for
defining the nature of concussion:
1. A direct blow to the head, face, neck or elsewhere on the body with an impulsive
force transmitted to the head.
2. Rapid onset of short-lived impairment of neurological function that resolves
spontaneously, or in some cases evolve over minutes to hours.
3. Acute clinical symptoms that represent primarily functional alterations, rather than
structural injury
4. Clinical signs and symptoms that may or may not involve loss of consciousness.
Resolution of the clinical and cognitive features typically follows a sequential
course, but in some cases prolonged recovery has been observed.
While useful, this statement does not include standardized diagnostic criteria for
clinical symptom-evaluation of concussion, although, most medical teams use common
concussion inventories78, including the Head Injury Scale79, Graded Symptom Checklist
(GSC)80, Balance Error Scoring System (BESS)81, 82, vestibular-ocular motor screening
(VOMS), Standard Assessment of Concussion (SAC)83, Concussion Symptom Inventory84,
and a collected version of these tests often called the Sport Concussion Assessment Tool
85, 86

. However, many assessments are subject to self-report symptoms or subjective

interpretations. Unfortunately, concussion is a clinical diagnosis without an objective gold
6

standard and relies heavily on subjective interpretation potentially preventing accurate
diagnosis and therefore management of concussion.
Biomechanics of Concussion
A concussion may occur when applied forces cause rapid changes to the velocity
vector of the brain which can be categorized according to their characteristics. Impact
forces are those forces which directly contact the head, whereas impulse forces are
transmitted to the head without direct contact, such as a blow to the body or pressure wave
87, 88

. Additionally, blast-induced neurotrauma (BINT), or concussions induced by an

explosions pressure wave are a major concern for U.S. military personnel whether actively
deployed in a war zone or in training89, 90. Regardless of impact or impulse each force can
be transferred to the brain and result in some degree of deformation91, 92.
Following force transmission to the head, the brain may experience two types of
movement: linear or rotational. Linear force is the application of force to the head’s center
of gravity, whereas rotational force is the non-central application of force that creates
rotational movement around the head’s center of gravity93. It has been suggested that linear
force results in a localized injury due to transient intracranial pressure alterations within
the brain and that rotational force induces diffuse injuries due to shearing force94, 95. While
most research is dedicated to the role of linear acceleration96, evidence suggests that both
linear and rotational forces occur in every concussion97 which may contribute to resultant
neurometabolic impairments98.
Acute Pathophysiology of Concussion
Biomechanical energy transference causes mechanoporation of neuronal plasma
membranes. This allows for excessive ionic fluctuation (i.e., potassium efflux, and sodium
and calcium influx) and glutamate release resulting in a feedforward loop of depolarization
7

and hyper excitability followed by a hypoactive “spreading depression-like state”16, 98, 99.
This subsequent hypoactive state may reflect neuronal refractory periods during which
ATP-dependent Na+-K+ pumps are hyperactive, attempting to restore resting ionic
concentrations. These Na+-K+ pumps require high levels of adenosine triphosphate (ATP)
which is typically replenished in the mitochondria by the slow but highly efficient oxidative
phosphorylation (i.e., 26 ATP per glucose). However, this period of Na+-K+ pump
hyperactivity rapidly depletes intracellular ATP reserves and to meet immediate energy
demands neurons revert to the rapid but inefficient glycolysis, which only produces 2 ATP
per glucose. This bioenergetic deficiency is also compounded by excessive calcium influx
and sequestration into the mitochondria100 further impairing oxidative phosphorylation101.
This resultant energy crisis is concurrent with normal or reduced cerebral blood flow, and
therefore no increase in solute delivery102, resulting in an uncoupling of energy supply and
demand16. Overall, this period of glucose hyper metabolism appears to be relatively
transient, lasting 30-minutes to several hours in animal models103. However, following the
hyper-metabolism of glucose there is a period of impaired glucose metabolism that can last
3 - 10 days and has been associated with behavioral and cognitive impairment104, 105.
Concussion is primarily considered to be a functional injury, however there is
evidence of structural alterations. Rapid acceleration changes to the brain apply shearing
forces to a neuron106, 107. Shearing force often results in microstructural axonal damage
called diffuse axonal injury (DAI), a well-established structural disruption post-injury and
has been associated with cognitive impairments, headache, dizziness, and fatigue107-111.
There are also reports of abnormal white matter integrity following concussion which has
been associated with neurocognitive impairments112. While some evidence exists reporting
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volumetric reductions in the frontal cortex, cerebellum, and hippocampus months after
concussion113-116, other studies have failed to find similar differences115.
Risk Factors for Concussion
There are several factors that may increase the probability of incurring a concussion
such as history of concussion, sport-type, sex, and preexisting disorders5. These may be
direct behavioral mechanisms such as a lapse in attention during dynamic sport
performance and being struck with an object, or a vulnerability factor such as the case in
neurodevelopmental disorders with pre-existing alterations to brain function and
bioenergetics which may decrease the threshold at which concussion occurs.
Researchers have established that having a history of concussion appears to
predispose athletes for future concussion. Multiple prospective studies have identified
history of concussion as a risk factor for subsequent concussion117-120. Athletes with prior
concussion demonstrated twice the likelihood of incurring a concussion, even when
adjusting for demographic factors (i.e., body-mass index, age) and sport criteria (i.e.,
contact level).
Sport-type is also considered a risk factor for concussion. Collision sports (i.e.,
football, ice hockey, rugby) have the highest rates of concussion for males at various levels
of competition18, 22, 118, 121, whereas females have higher rates for concussion in soccer,
basketball, and ice hockey at different levels of competition122. Interestingly, compared to
males in ice hockey, females demonstrated significant greater injury rates, despite
prohibition of body checking in female ice hockey122.
The potential influence of sex characteristics on concussion incidence has expanded
rapidly. When specifically examining similar sports (i.e., soccer, basketball, etc.) female
athletes have greater risk for concussion than males122-124. Furthermore, female athletes
9

appear to report greater symptom burden following concussion125 as well as prolonged
symptoms three months post-injury126, although when compared to males in the same
sports recovery rates normalize127. The mechanisms of injury also appear different, males
showed greater percentage of player contact concussions, whereas females showed greater
percentage of concussion resulting from contact with the playing surface or ball122. These
trends remain underexplored regarding biomechanical (e.g., joint angles), physiological
(e.g., hormonal differences), and sociocultural (e.g., females may be more honest in
reporting symptoms) factors which may elucidate potential sex differences61, to date
however there is no consensus of the mechanisms by which sex modifies risk.
Acute Signs and Symptoms
Studies using advanced neuroimaging techniques have consistently demonstrated
that structural and functional alterations are associated with a wide range of signs and
symptoms following injury11, 98, 113, 128-133 that are most severe within the first week postinjury5. Signs are objective and visible by some other individual (e.g. balance problems or
loss of consciousness), whereas a symptom is some phenomenon experienced by the
patient (e.g., headache or fatigue)134. Signs and symptoms of concussion are generally
categorized as physical, cognitive, emotional, and sleep related, with some overlap135, we
will refer to signs and symptoms collectively as ‘presentation’.
Physical presentation of concussion may include headache, nausea, vomiting,
balance problems, dizziness, light/sound sensitivity, and fatigue. Among physical
presentations, headache is the most commonly reported symptom, followed by balance
problems, dizziness, and fatigue following concussion136. Cognitive presentation is often
determined by a combination of athlete self-report, and computerized neurocognitive
testing (CNT). Athletes often report feeling foggy or feeling slowed down (i.e., cognitive
10

processing speed), difficulty concentrating (i.e., attention), or problems remembering (i.e.,
memory)136. Emotional presentation is commonly reported as anxiety, depression, and
other mood disruptions (e.g., anger)137. Sleep is considered a potential marker for
predicting recovery138, 139, and athletes may report sleep disruptions such as difficulties
falling asleep, staying asleep, sleeping more or less than usual140. Among all signs and
symptoms of concussion, the most obvious indicator is a loss of consciousness (LOC),
however, this event occurs in less than 10% of concussions141. Similarly, athletes may
present varying degrees of retrograde or anterograde amnesia, both LOC and amnesia may
be important indicators of more serious injury141. Whether injury localization plays a
significant role in modulating the severity of signs and symptoms following concussion is
a matter of some debate. However, the neurometabolic alterations in the acute phase are
strongly correlated with symptom severity142.
Acute Management
Generally, mean symptom recovery occurs in about 14 days5,

143

, and seems

relatively consistent with the associated neurometabolic cascade and impairments
following concussion16,

128

. While this period is considered “normal recovery”, it is

important to distinguish clinical symptomology from neurological recovery. McCrea et
al.143 found that concussed athletes reported greater symptoms at 7-days post injury,
relative to their own baseline symptoms, however, even at 90-days post-injury concussed
players performed more poorly than controls on neurocognitive measures. However, Henry
et al.144 examined 66 concussed athletes using similar measures and reported that total
symptoms resolution occurred between 21 to 28 days after injury. Intriguingly, both studies
report the greatest symptom improvement during the first two weeks, with domain-specific
neurocognitive impairments lingering beyond clinical symptom resolution. Accordingly,
11

the transient view of concussion has undergone scrutiny as evidence of persisting subclinical deficits accumulates6-14.
The clinical evaluation of concussion has evolved beyond clinical measures to
incorporate multi-modal assessments of cognitive, neurophysiological, and psychological
function5 as the search for more objective biomarkers recovery continues145, 146. Research
has grown exponentially in recent years regarding the nature of concussion, risk factors,
outcomes, treatments, rule changes, and equipment related concerns147-150. Subsequently,
experts agree the heterogeneous nature of concussion causality coupled with unique
demographic characteristics of an athlete can synergistically alter the manifestation,
severity, and duration of symptoms151-153. Among these characteristics, existing literature
demonstrates that pre-existing conditions such as anxiety and depression154, migraine152,
neurodevelopmental disorders26, 50, 61, 155, and concussion history5 can negatively influence
outcomes following concussion.
Attention Deficit Hyperactivity Disorder
Prevalence
Attention Deficit Hyperactivity Disorder (ADHD) is prevalent in 6% of children
and adolescents156 and 5% of adults. While the prevalence of ADHD in college athletes
has not been epidemiologically studied, some evidence exists to suggest ADHD occurs in
7% - 10% of college athletes26, 50.
Definition and Diagnosis
ADHD is characterized by age or developmentally inappropriate levels of
inattention, hyperactivity, impulsivity, and risk-taking behaviors29 that persist into
adulthood for approximately 70% of cases, with varying degrees of severity157. ADHD is
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typically observed during childhood as chronic impairments to attention and self-regulation
during situations which require self-monitoring157-160. The hallmark triad—inattention,
hyperactivity, and impulsivity—are chronic and relatively stable across the lifespan161.
There is no dichotomous test for ADHD, rather clinicians must “rule in” the probability of
ADHD based on self-, parent-, and observational report of symptoms29. To aid in the proper
diagnosis of ADHD, as opposed to another disorder (e.g., oppositional defiant disorder),
updated versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM)
contain commonly used criteria for defining and diagnosing ADHD in the United States29.
ADHD is divided into subtypes categorized by the presence of six out of nine
symptoms within one of two distinct lists, inattention, and hyperactivity-impulsivity. These
symptoms must have been present for at least six months and at an inappropriate age or
developmental level. In this way, individuals are categorized as either inattentive (ADHDI), hyperactive-impulsive (ADHD-HI), or a combined (ADHD-C) subtype. However, the
design of DSM diagnostic criteria emerged from field trials with children and no adults
were included162. Although, a recent systematic review demonstrates that an overall ADHD
diagnosis (i.e., unspecified sub-type) in adults is reliable and consistent161.
ADHD is considered an impairment of behavioral inhibition (i.e., disinhibition) and
self-regulation 163 which suggests impaired executive functionality

164-166

. Generally, it is

agreed there are three core executive functions: inhibition (e.g., behavioral, and cognitive
inhibition), working memory, and cognitive flexibility164, 167-169. Disinhibition may result
in acting or responding before processing the appropriate contextual features of a situation.
Behavioral disinhibition may manifest as hyperactivity (e.g., inability to wait for their turn)
or impulsive actions (e.g., crossing the street without looking) consequently resulting in
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risky behaviors. Cognitive disinhibition may manifest as inattentive behaviors (e.g., failing
to attend to instructions), or impulsive responses (i.e., responding before thinking).
Silverstein et al.170 reported that symptoms of ADHD were significantly correlated with
executive dysfunction. Indeed, a plethora of studies have demonstrated that executive
functions are impaired in individuals with ADHD resulting in poor cognitive
performance42, 170-185. These overall reductions in executive function contributes to lifelong
difficulties such as mood disorders (i.e., anxiety depression)30-39, social impairments40, 41,
academic difficulty42, poor vocational performance43, vehicular accidents44, 45, and bodily
injuries46 observed in ADHD. There is some data to suggest that males with ADHD may
experience greater severity of and variance in symptoms than females with ADHD.55, 186
Pathophysiology and impairments of ADHD
Currently, a single underlying cause of ADHD has not been identified, and ADHD
is most likely a confluence of genetic and environmental factors which synergistically
contribute to clinical features of ADHD. This multifactorial etiology is reflected in the
heterogeneity of symptoms, outcomes, and extensive comorbidities in individuals with
ADHD. Though there is no single underlying etiology, there are several factors that are
strongly associated with ADHD. ADHD is a heritable disorder with twenty twin studies
demonstrate a 76% heritability rate187. Similarly, 25% of adults with ADHD reported
having a parent also diagnosed with ADHD188. There are several genetic association studies
with dissimilar findings and small sample sizes189 and attributing specific genes with
causation is a somewhat controversial topic in ADHD research. However, genetic variants
of dopamine receptors (i.e., D1, D2, D3, D4, D5 receptors) and dopamine transporters
remain of great interest to researchers187. While independent genetic variants alone are
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considered insufficient to be causative, however when combined with environmental
factors the cumulative effect may reflect ADHD symptomology. For example, a genetic
variant of the dopamine transport protein DAT1 combine with prenatal exposure to alcohol,
and nicotine have been shown to increase risk for ADHD and common symptoms, such as
hyperactivity and impulsivity 190-192.
There are numerous studies demonstrating significant structural brain alterations in
ADHD. The most common finding is a reduction in overall brain volume particularly in
frontal regions and regional connectivity pathways 193-196. There are volumetric reductions
throughout the frontal lobe particularly the prefrontal cortex (PFC) in ADHD

197-199

.

Furthermore, the dorsolateral prefrontal cortex (DLPFC) is reported to have reduced grey
and white matter density, asymmetric activation200-204 and white matter tracts linking the
prefrontal cortex to other brain areas is less organized and functional connectivity is
reduced 205.
ADHD related structural impairments may result in less effective prefrontal
regulation of cortical and subcortical structures, resulting in diminished top-down selfregulation and the hallmark characteristics of ADHD206-209. The PFC plays an integral role
in cognitive processing related to reward, emotional processing, response inhibition, and
attention. The PFC uses a network of interconnected pyramidal neurons that are selfexcitatory, that is they can excite each absent environmental stimulus, thus they may be
considered a “mental sketch pad”210. Additionally, a vast network of projections to sensory
association areas enable PFC to suppress processing of irrelevant stimuli (i.e., distractors)
while enhancing attention to important yet boring stimuli211. Depending on task demands,
the PFC can also sustain attention to a single task212 or rapidly shift attention for
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multitasking

213

. In addition to attention regulation, the PFC is also vital for regulating

emotions and behaviors. The right inferior PFC is of particularly important for minimizing
impulsive behaviors and inhibiting inappropriate actions214 while orbital and ventromedial
PFC regulate emotions215. Furthermore, the medial PFC is a key node of the default mode
network (DMN), an intrinsic network primarily signaling a state of rest reflecting a
physiological baseline activity of the brain216-220. As cognitive loading or demand increase
the DMN is attenuated by the task-positive network (TPN) of the dorsolateral prefrontal
cortex (DLPFC)221. Therefore, structural alterations, reduced volume or activation of the
DLPFC may result in failure of the TPN to sufficiently suppress the DMN, which interferes
with task performance222, and result in slower reaction times and inaccurate attention
control223.
Beyond structural alterations, there is an 8.1% reduction in global glucose
metabolism during an auditory-attention task in ADHD, with particular decrements in
prefrontal (e.g., attention) and premotor (i.e., motor control) areas224. Also, Schweitzer et
al.225, found reduced cerebral blood flow (CBF) in frontal areas during a working memory
task among individuals with ADHD. This reduction in CBF suggests that there is reduced
activation in frontal areas226, 227.
Structural and metabolic impairments also modify aspects of neurotransmitter (NT)
bioavailability, including regional activation and biosynthesis. Indeed, dysregulation of
catecholaminergic (i.e., dopamine and norepinephrine) signaling is regularly reported in
ADHD 228-230. Dopamine (DA) is a neurotransmitter (NT) believed to play important roles
in

regulating

cognition,

attention,

movement,

motivation,

and

reward231-234.

Norepinephrine (NE) is another NT associated with arousal, set-shifting and sustained
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attention235. Furthermore, DA is a precursor for NE, via mechanism of dopamine βhydroxylase, an enzyme which catalyzes the conversion of DA into NE and thus helps to
balance DA and NE concentrations in the brain. Therefore, abnormalities in DA signaling
or altering DA concentrations will subsequently increase NE concentrations236.
Thus, the PFC environment is extremely sensitive to alterations in the
neurochemical environment and require that catecholamine concentration levels are
maintained at optimal levels for proper functioning further demonstrated by positive
influence of increased dopamine in healthy controls237. PFC concentrations of these NTs
are positively associated with arousal level. For example, during low arousal conditions,
NT concentrations are low238, 239. Indeed, low levels of catecholamines are known to impair
executive functions in the prefrontal cortex, to such a degree that they mimic most
symptoms of ADHD240. Additionally, alterations to TPN/DMN synchronization modifies
the basal arousal state, subsequently changing the availability of catecholamines, thus
modifying PFC activity and therefore executive functions. Collectively, the evidence
suggests that many behaviors and outcomes associated with executive dysfunction in
ADHD result from a variety of structural, metabolic, and biochemical alterations.
Management
Currently, the most common approach to treating ADHD are psychostimulant
medications241. These psychostimulant medications directly cause an increase in synaptic
NT concentrations, resulting in increased neuronal activity and therefore activation of a
circuit, or network. In sum, the magnitude of neuronal receptor activation depends on 1)
the quantity of the NT (e.g., amount of NT released), 2) the duration the NT remains in the
synaptic cleft (e.g., time until reuptake/degradation), and 3) receptor concentration for a
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NT. Normally, specialized transport proteins actively transport NTs back into the cell to
decrease synaptic concentrations so that 1) postsynaptic activation is limited and 2) NTs
are recycled for homeostatic efficiency242. These are important considerations to consider
because psychostimulant medications manipulate these processes to improve cognitive
processing and attention in individuals with ADHD.
Currently, the Food and Drug Administration (FDA) have only approved two
psychostimulant molecules, amphetamine (AMPH), and methylphenidate (MPH)243. There
are numerous brand names and preparations (e.g., Ritalin, Adderall, etc.) however, we will
henceforth use the generic names AMPH and MPH. While both stimulants primarily act to
enhance the effects of dopamine and/or norepinephrine, each operate via slightly different
mechanisms.
AMPH acts as a “reverse-transport” mechanism that is AMPH binds to dopamine
active transport proteins (DAT) and they now actively carrying dopamine out of the
cytoplasm and into the synaptic cleft244. Additionally AMPH inhibits vesicular packaging
of dopamine, thus increasing cytoplasmic dopamine concentrations ready for “reverse
transport”244. Thus, AMPH decreases dopamine reuptake and increases release, thereby
increasing synaptic cleft concentrations, enhancing dopaminergic activation and
functionality, particularly in the PFC.
MPH actively blocks the reuptake of dopamine and norepinephrine from the
synaptic cleft increasing the duration in which these NTs can act on their receptors,
however unlike AMPH it does not interfere with vesicular packaging245. In addition to
these direct catecholaminergic effects, MPH has been shown to improve the TPN/DMN
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synchronization, that is oscillatory variations in activation patterns are normalized allowing
more optimal cognitive functioning246, 247.
Regardless of their mechanism of action, the catecholaminergic activity caused by
these stimulant medications demonstrate a dose-effect response, that is too much or too
little can be just as detrimental248. With appropriate dosing, medications which increase the
availability of catecholamines optimize the neurochemical environment which enhances
executive functions and therefore outcomes (e.g., academic performance, behaviors, etc.)73,
249, 250

.

Concussion and ADHD
Given the significant overlap of physiological impairments and symptoms between
concussion and ADHD, the current consensus is to consider ADHD a modifier for
increased risk for, and atypical recovery from concussion5. However, there is relatively
sparse conformational evidence in adult athletes with ADHD as most research in this area
has focused on children and adolescent athletes. In a retrospective study with a limited
sample size, Alosco et al.26 reported college athletes with ADHD may have greater history
of single and multiple concussions. Similarly, an aggregate study by Nelson et al.50
reported that college athletes with ADHD have 2.93 (95% CI 2.05 – 4.19) times the
prevalence of a history of three or more concussions, relative to controls. It important to
note that this study was primarily male (97%) potentially neglecting concussion-related
sex differences. In the general population, female athletes appear to have greater risk for
incurring a concussion,122-124 however it remains unknown whether ADHD compounds or
supersedes sex differences regarding risk for concussion. It is possible that the reported
increased ADHD severity in males would result in a similar risk for concussion among
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females with ADHD. Thus far, all findings have been cross-sectional. While these studies
provide important information, without establishing temporality, no inferences regarding
causation can be made. To date, no longitudinal studies regarding concussion likelihood in
college athletes with ADHD exist.
There is also evidence to suggest athletes with ADHD demonstrate concussion-like
symptoms at baseline which reflect inherent characteristics of ADHD. Several studies have
reported that college athletes absent a history of concussion, but with ADHD demonstrated
concussion-like symptoms at baseline, such as “problems learning”, “emotional lability”,
“difficulty concentrating”, and “difficulty remembering”50, 56. Of note, these symptoms
share significant overlap with the inattentiveness among individuals with ADHD which
commonly persists into adulthood251. The importance of this consideration cannot be
overstated since most computerized cognitive tests (CNTs), and common clinical scales
utilize normative data to determine levels of acceptable performance useful for determining
clinical recovery. However, the Immediate Post-Concussion Assessment and Cognitive
Testing battery (ImPACT) does provide a “special education” group for the total symptom
score that may reflect average symptoms in populations with preexisting disorders, but the
samples are heterogeneous and remain in the early phase of development. Furthermore, the
ImPACT uses an algorithm to provide a marker for ‘invalid results’ that are determined by
more impulsive responses, misunderstanding instructions, deliberate under-performance,
or other factors. Among these factors, of major concern for athletes with ADHD are those
of impulsive responses (i.e., poor response inhibition or inattention), and misunderstanding
instructions (i.e., cognitive control or inattention). Therefore, it is possible that among
athletes with ADHD, ‘invalid’ results may represent greater ADHD symptomology rather
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than truly being ‘invalid’.252 Understanding the pre-injury profile of athletes with ADHD
is of utmost importance when interpreting post-injury results due to potentially
confounding pre-existing symptoms.
Further compounding concussion management in athletes with ADHD is stimulant
medications (i.e., Amphetamines and Methylphenidate), the front-line treatments for
ADHD62-64. Research has consistently demonstrated that stimulant medications enhance
executive functions (i.e., working memory, inhibition, attentional focus), and functional
outcomes of daily activities in both individuals with ADHD and healthy controls65, 69-71.
Stimulant medications are known to influence performance on neurocognitive test
commonly used in the management of concussion59, 63, 65-68. Indeed, a recent study by Cook
et al.54 reported that athletes with un-medicated ADHD had greater rates of invalid
ImPACT results, compared to those with medicated ADHD on a pre-season baseline
assessment. Furthermore, this study also demonstrated that athletes with medicated ADHD
showed no differences either in rate of invalid results or in cognitive performance than
controls. To date only one study has investigated the influence of stimulant medication preand post-concussion66. Unmedicated athletes with ADHD demonstrated poorer
performance for verbal, and visual memory, visual motor speed, and slower reaction times
than controls pre- and post-concussion, however, medicated athletes with ADHD
demonstrated similar visual motor speed and reaction time to controls, pre- and postconcussion.
Collectively, the symptoms of concussion and ADHD have many similarities and
some of these symptoms may share some physiological disruptions. However, prior to
dedicating significant resources (i.e., financial, time, workforce) to investigating
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underlying etiology, we must first unravel whether 1) there is a relationship between
incidence of concussion and ADHD, and 2) whether the symptoms of concussion are
compounded by the presence of ADHD. In so doing, we stand to further enhance our
knowledge base regarding 1) whether athletes with ADHD are more likely to incur a
concussion, and 2) the synergistic nature of concussion symptoms regarding the degree to
which pre-injury concussion-like symptoms are exacerbated.
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CHAPTER 3: AIMS & METHODS
Specific aim 1: To determine the likelihood of having experienced a concussion among
male and female athletes with ADHD. We hypothesize that:
1. Hypothesis 1a: Athletes with ADHD will have greater odds of single and multiple
concussions, relative to athletes without ADHD.
2. Hypothesis 1b: Both male and female athletes with ADHD will have greater odds
of single and multiple concussions, relative to biological sex specific athletes
without ADHD.
3. Hypothesis 1c: Female athletes with ADHD would not have greater odds of single
or multiple concussions, relative to male athletes with ADHD.
Specific aim 2: To determine the likelihood of incurring a concussion among male and
female athletes with ADHD. We hypothesize that:
1. Hypothesis 2a: Athletes with ADHD will have greater risk for incurring a
concussion, irrespective of concussion history, relative to athletes without ADHD.
2. Hypothesis 2b: Both male and female athletes with ADHD will have greater risk
for incurring a concussion, irrespective of concussion history, relative to biological
sex specific athletes without ADHD.
3. Hypothesis 2c: Female athletes with ADHD will not have greater risk for incurring
a concussion, irrespective of concussion history, relative to male athletes with
ADHD.
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Specific aim 3: To evaluate whether medication status influences concussion symptom
profiles throughout recovery in athletes with ADHD. We hypothesize that:
1. Hypothesis 3a: Athletes with un-medicated ADHD will perform worse on ImPACT
measures and symptom reports at baseline than athletes with medicated ADHD,
and athletes without ADHD.
2. Hypothesis 3b: Athletes with un-medicated ADHD will perform worse on ImPACT
measures and symptom reports at 24-48 hours post injury than athletes with
medicated ADHD, and athletes without ADHD.
3. Hypothesis 3c: Athletes with un-medicated ADHD will take longer to be cleared
for unrestricted return-to-play than athletes with medicated ADHD, and athletes
without ADHD.
Methodology
For all specific aims, a de-identified database was provided by the National
Collegiate Athletic Association Department of Defense Grand Alliance (NCAA-DOD):
Concussion Assessment, Research and Education (CARE) Consortium. The CARE
Consortium enrolled over 34,000 unique athletes and military service academy members
and consisted of multiyear multimodal assessment of the natural concussion history,
described in detail elsewhere.253 All athletes and cadets signed a site-specific institutional
review board approved consent form, also approved by the US Army Medical Research
and Materiel Command Human Research Protection Office253. In brief, prior to the onset
of specific sport-seasons or academic year all participants received a comprehensive
demographics and health history questionnaire including questions regarding prior ADHD
diagnoses and medications and completed a clinical concussion battery as baseline.
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Concussions occurring after CARE enrollment were verified by team medical personnel
using evidence-based DoD criteria254. These concussed athletes were reassessed at multiple
time points across recovery: within 6-hours of injury, 24-48 hours post-injury, time when
asymptomatic, time of unrestricted return-to-play, and six months post-injury.
Participants
We categorized according to their answers into control and ADHD groups. ADHD
was a self-report of physician diagnosis. All athletes who reported another disorder (e.g.,
learning disability, autism spectrum disorder), brain surgery, history of migraines, severe
brain injury, or psychological disorders (e.g., schizophrenia, bipolar disorders, etc.), or take
psychological medications other than psychostimulants (e.g., anti-psychotics) will be
excluded from analysis. Intramural athletes and military service academy cadets will be
grouped as ‘non-NCAA’ athletes for NCAA contact category analyses, varsity athletes at
the academies will be categorized into standard NCAA contact categories. Control athletes
who reported no diagnoses of ADHD but repeated a year of school or reported prior
individualized education program (IEP) or a 504 plan were excluded from analyses to
control for possible undiagnosed or unreported ADHD. Additionally, for all aims, control
athletes who reported taking psychostimulant medications were excluded from analysis.
Specific aim 3
Only for specific aim 3, athletes with ADHD were further stratified by whether they are
taking psychostimulant medication (ADHD+Rx, or not taking medication (ADHD_uRx).
We defined psychostimulant medications as any brand using Amphetamine or
Methylphenidate, and athletes taking other prescription medications will be excluded from
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analyses. Only concussed athletes with complete ImPACT performances at baseline, 2448 hours post-injury, and unrestricted return-to-play (uRTP) were included.
Eligible participants were grouped into 1) controls, 2) ADHD+Rx, 3) ADHD_uRx).
We used double-matched controls based on biological sex, age, body-mass index, and
history of diagnosed concussion.
Assessment Measures
The ImPACT is a 25-minute computerized neurocognitive tests which evaluates
impulse control, reaction time, total symptoms, verbal memory, visual memory, visual
motor speed, and cognitive efficiency. We will examine performance in each measure at
baseline, 24-48 hours post-injury, and at uRTP. uRTP was determined by medical staff
clearance after completing all stages of a return-to-play progression.78, 255, 256 Herein, we
define recovery as duration of symptoms as reported in the clinical battery and symptom
inventory prior to uRTP.
All significant outliers (± 2 times the standard deviation) were removed following
within group analyses prior to final matching. A one-way analysis of variance (ANOVA)
with Tukey post hoc correction revealed no statistically significant differences exist
between groups for age, body-mass index, and concussion history.
Statistical Analysis
All analyses were performed using SPSS (Version 26; SPSS Inc., Chicago, IL).
Specific aim 1: To determine the likelihood of having experienced a concussion among
male and female athletes with ADHD.
Retrospective odds ratios (ORs) with 95% confidence intervals (CIs) were
calculated across three contexts: 1) Odds of having any concussion history prior to
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enrollment, 2) odds of having had a single concussion prior to enrollment, and 3) odds of
having a history of multiple concussions prior to enrollment. Each context was separately
analyzed 1) by group relative to controls (i.e., ADHD vs controls), 2) within sexes (e.g.,
males with ADHD vs. males without ADHD), and 3) between sexes (e.g., females with
ADHD vs. males with ADHD).
To control for potential sport-contact type bias, we further stratified groups by
similar sports by NCAA contact, NCAA limited-contact, NCAA non-contact sports, and
non-NCAA and repeated analyses 1) by group, and 2) between sexes.
Specific aim 2: To determine the likelihood of incurring a concussion among male and
female athletes with ADHD.
Prospective estimates of relative risk (RRs) with 95% CIs were calculated across
three contexts: 1) Risk for incurring a concussion, 2) risk incurring a concussion with
concussion history, and 3) risk for incurring a concussion absent concussion history. Each
context will be separately analyzed 1) by group relative to controls (i.e., ADHD vs
controls), 2) within sexes (e.g., males with ADHD vs. males without ADHD), and 3)
between sexes (e.g., females with ADHD vs. males with ADHD).
To control for potential sport-contact type bias, we further stratified groups by
similar sports by NCAA contact, NCAA limited-contact, NCAA non-contact sports, and
non-NCAA and repeated analyses 1) by group, and 2) between sexes.
Specific aim 3: To evaluate whether medication status influences concussion symptom
profiles throughout recovery in athletes with ADHD.
Using our participant inclusion and grouping criteria for specific aim 3, a one-way
ANOVA was used to identify baseline differences for all ImPACT measures (i.e., impulse

27

control, reaction time, total symptoms, verbal memory, visual memory, visual motor speed,
and cognitive efficiency) between groups. A repeated measures ANOVA for all ImPACT
measures was used as the within-subjects factor and group as the between-subjects factor
will be performed to examine whether cognitive performance is different for each ImPACT
measure throughout recovery. Significant interactions will be decomposed using a
univariate ANOVA using baseline ImPACT values as a between groups covariate to
account for pre-existing differences in ImPACT score/performance.
A one-way ANOVA with Tukey post hoc correction was used to determine whether
there were differences between groups for days between injury and: reporting the injury,
being determined clinically asymptomatic, eligible for return-to-play, and symptom
resolution.
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CHAPTER 4: RESULTS
Inclusion and exclusion criteria for aims 1 and 2 are provided in Figure 4.1.
Specific Aim 1
Final analyses included 32,635 athletes comprised of 31,122 controls and 1,513
athletes with ADHD. Sample characteristics are provided in Table 4.1. Retrospective odds
can be found in Tables 4.2 & 4.3.
Overall odds: Analyses revealed that athletes with ADHD had greater odds of
having a concussion history (Odds Ratio; OR = 1.915, 95%CI 1.72 – 2.14), and further
investigation substantiated this finding for both single (OR = 1.699, 95%CI 1.51 - .1.92)
and multiple prior concussions (OR = 1.914, 95%CI 1.60 – 2.29) relative to control
athletes.
Odds within sex: Analyses revealed that among female athletes, those with ADHD
had greater odds of having a concussion history (OR = 1.931, 95%CI 1.52 – 2.21), and
further investigation substantiated this finding for both single (OR = 1.742, 95%CI 1.422.14) and multiple prior concussions (OR = 1.592, 95%CI 1.17 – 2.18) relative to female
control athletes.
Analyses revealed that among male athletes, those with ADHD had greater odds of
having a concussion history (OR = 1.956, 95%CI 1.71 – 2.24), and further investigation
substantiated this finding for both single (OR = 1.670, 95%CI 1.44 – 1.93) and multiple
prior concussions (OR = 2.120, 95%CI 1.71 – 2.63) relative to male control athletes.
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Odds between sexes: An exploratory analysis between sexes among control athletes
revealed that females had slightly reduced overall odds of concussion (OR = .940, 95%CI
.889 – .995) relative to males. Further investigation revealed that while females had
reduced odds of a single concussion (OR = .885, 95%CI .931 - .941), however females had
greater odds of multiple prior concussions (OR = 1.132, 95%CI 1.023 - 1.253) relative to
male athletes.
No significant differences were found among athletes with ADHD when comparing
female to male athletes’ odds of overall (OR = .880, 95% CI .704 – 1.100), single (OR =
.923, 95% CI .723 – 1.178), or multiple prior concussions (OR = .850, 95% CI .589 –
1.226).
Overall odds by contact category: Analyses revealed that athletes with ADHD had
greater odds of concussion in contact (OR = 1.727, 95%CI 1.478 – 2.019), limited contact
(OR = 1.770, 95%CI 1.404 - 2.232), non-contact (OR = 1.720, 95%CI 1.286 – 2.301) and
non-NCAA categories (OR = 2.030, 95%CI 1.473 – 2.797) relative to category specific
controls.
Odds by contact category between sexes: An exploratory analysis between sexes
among control athletes revealed that females had greater overall odds of concussion history
in contact (OR = 1.151, 95%CI 1.050 – 1.261) and non-contact categories (OR = 1.439,
95%CI 1.208 – 1.715), but reduced odds of concussion history in the non-NCAA category
(OR = .878, 95% CI .771 – 1.00), relative to category specific male controls.
Among athletes with ADHD in the non-contact category, females had greater odds
of concussion (OR = 1.974, 95%CI 1.082 – 3.601) than male athletes. There were no
significant differences were found between females and males with ADHD among contact
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(OR = .959, 95% CI .676 – 1.358), limited contact (OR = .820, 95% CI .522 – 1.288), or
non-NCAA categories (OR = 1.346, 95% CI .577 – 3.140).
Specific Aim 2
Sample characteristics are provided in Table 4.4. Prospective relative risk estimates can be
found in Tables 4.5 & 4.6.
Overall risk: Analyses revealed that athletes with ADHD had greater risk for
concussion (Relative Risk Ratio; RR = 1.236, 95%CI 1.059 – 1.443). However, no
significant differences were found among athletes with ADHD without history (RR =
1.041, 95% CI .825 – 1.340) or with history of concussion (RR = 1.195, 95% CI .973 –
1.47).
Risk within sex: Analyses revealed that among female athletes, those with ADHD
had greater risk of incurring a concussion history (RR = 1.044, 95% CI .797 – 1.369).
Analyses failed to reveal significant differences between female athletes with ADHD
without history (RR = .802, 95% CI .526 – 1.221), or with history of concussion (RR =
1.096, 95% CI .776 – 1.547), relative to female controls.
Analyses revealed that among male athletes, those with ADHD had greater risk for
concussion (RR = 1.369, 95% CI 1.133 – 1.654) than male controls. However, no
significant differences were found among male athletes with ADHD without history (RR
= 1.204, 95% CI .911 – 1.592) or with history of concussion (RR = 1.272, 95% CI .985 –
1.644).
Risk between sexes: An exploratory analysis between sexes among control athletes
revealed that female athletes had greater overall risk for concussion (RR = 1.194, 95% CI
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1.107 – 1.287), without history (RR = 1.180, 95% CI 1.073 – 1.297), and with history of
concussion (RR = 1.249, 95% CI 1.105 – 1.412) relative to male control athletes.
Analyses failed to reveal significant differences among athletes with ADHD when
comparing female to male athletes for overall risk for concussion (RR = .911, 95% CI .661
– 1.255), without history (RR = 1.076, 95% CI .71 – 1.624), or without history of
concussion (RR = .785, 95% CI .478 – 1.289).
Risk by contact category: Analyses failed to reveal significant differences between
athletes with ADHD and control for risk of concussion in any contact category (RR ranges
= .931 – 1.396).
Risk by contact category between sexes: An exploratory analysis between sexes
among control athletes revealed that females had greater risk for concussion than male
control athletes in limited contact (RR = 2.332, 95% CI 1.936 – 3.080), non-contact (RR =
1.546, 95% CI 1.136 – 2.103), and non-NCAA (RR = 2.199, 95% CI 1.905 – 2.539))
categories.
Analyses failed to reveal significant differences between female and male athletes
with ADHD for risk of concussion in any contact category (RR ranges = 1.025 – 3.226).
Specific Aim 3
Inclusion and exclusion criteria for aim 3 are provided in Figure 4.2 Final analyses
included 210 athletes comprised of 140 controls double-matched to 35 athletes with ADHD
taking psychostimulant medications (ADHD+Rx), and 35 athletes with ADHD but not
taking

psychostimulant medications

(ADHD_uRx).

Sample characteristics

and

accompanying statistics are provided in Table 4.7. The ADHD_uRx group demonstrated a
statistically significant larger BMI than controls. There were no significant differences
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between groups for age at baseline, age at injury during the study, or for the age at which
the athletes incurred their first ever concussion among athletes with a positive concussion
history. The ADHD_uRx group reported significantly greater history of concussion (60%)
than both controls (35.7%) and ADHD+Rx (28.6%). There were no differences between
groups in the amount of time between the injury and reporting the injury, being
programmatically determined to be asymptomatic, or being programmatically determined
eligible for RTP (14-15 days). However, the ADHD_uRx reported a greater number of
days with self-reported concussion related symptoms (9 days) than both controls (5 days)
and ADHD+Rx (6 days).
ANOVA post-hoc results for baseline and results for 24-48 hours post injury and
uRTP post-hoc comparisons can be found in Table 4.9. Pairwise effect sizes suggest most
effect sizes were small-to-medium (η2 from .01 to .101) suggesting caution may be needed
for clinical or practical interpretation.257
Baseline: Analyses revealed that the ADHD_uRx group performed significantly worse
than controls for impulse control (7.343 vs. 4.686), reaction time (0.631 vs. 0.584), and
visual motor speed (38.350 vs. 42.602). There were no statistically significant differences
between ADHD+Rx and ADHD_uRx groups for any other baseline ImPACT measure.
24-48hours post-injury: Analyses using baseline scores as a covariate revealed that the
ADHD+Rx group performed worse than controls for impulse control (9.40 vs. 6.07).
Additionally, the ADHD_uRx group performed significantly worse than controls for
reaction time (.683 vs. .606), visual memory (69.5 vs. 75.3), and cognitive efficiency (.281
vs. .367). Furthermore, the ADHD_uRx group performed worse than both controls and
ADHD+Rx for visual motor speed (35.248 vs. 39.331 and 42.156), this was the only
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difference between ADHD+Rx and ADHD_uRx for any 24-48hour post-injury ImPACT
measure.
Unrestricted return-to-play (uRTP): Analyses using baseline scores as a covariate revealed
the ADHD+Rx group performed significantly worse than both controls and ADHD_uRx
for impulse control (9.057 vs. 5.771 and 5.829). Also, the ADHD_uRX and ADHD+Rx
groups reported greater total symptoms than controls (1.429 and 1.486 vs. .629).
Additionally, the ADHD_uRx group performed significantly worse than controls for verbal
memory (87.857 vs. 92.029), visual memory, and visual motor speed (41.877 vs. 44.974).
Furthermore, the ADHD_uRx group performed worse than both controls and ADHD+Rx
for reaction time (.608 vs. .567 and .565). There were no differences between groups for
cognitive efficiency at uRTP.
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Tables & Figures
Total Athletes = 47,444
Excluded (n = 12,810)
Year 2 (n = 11,218)
Year 3 (n = 1,589)
Year 4 (n = 3)
Unique Athletes (n = 34,634)
Excluded for other diagnosis (n = 752)
Specific Learning Disorder (n = 429)
ADHD and Specific Learning Disorder (n = 323)
Controls (n = 32,369)
Excluded (n = 1,247)
Missing Sex (n = 8)
Failed a year (n = 1,239)
Controls (n = 31,122)

ADHD (n = 1,513)

Figure 4.1. Selection Criteria for Specific Aims 1 & 2
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Table 4.1 Sample Characteristics for Aim 1.
Controls
No History
n
Overall History (n = 7398)

%

ADHD

History
n

%

No History
n

%

History
n

%

24256 77.9 6866 22.1 981

64.8

532 35.2

Female (n = 2681)

9205

78.6 2506 21.4 351

66.7

175 33.3

Male (n = 4717)

15051 77.5 4360 22.5 630

63.8

357 36.2

Concussion History by Quantity
One Prior (n = 5607)

-

-

5221 93.1

-

-

386

6.9

Female (n = 1970)

-

-

1841 93.5

-

-

129

6.5

Male (n = 3637)

-

-

3380 92.9

-

-

257

7.1

-

-

1645 91.8

-

-

146

8.2

Female (n = 711)

-

-

665

93.5

-

-

46

6.5

Male (n = 1080)

-

-

980

90.7

-

-

100

9.3

Two + Prior (n = 1791)

Concussion History by Contact Category
Contact (n = 3508)

7026

68.7 3204 31.3 386

55.9

304 44.1

Female (n = 1043)

1923

66.5

97

56.7

74

Male (n = 2465)

5103

69.5 2235 30.5 289

55.7

230 44.3

5400

80.8 1284 19.2 259

70.4

109 29.6

Female (n = 708)

2834

81.1

662

18.9 122

72.6

46

27.4

Male (n = 685)

2566

80.5

622

19.5 137

68.5

63

31.5

Non-Contact (n = 794)

4101

84.9

730

15.1 209

76.6

64

23.4

Female (n = 576)

2664

83.4

531

16.6 114

71.7

45

28.3

Male (n = 218)

1437

87.8

199

12.2

95

83.3

19

16.7

Non-NCAA (n = 1704)

7728

82.4 1649 17.6 127

69.8

55

30.2

Female (n = 354)

1784

83.8

18

64.3

10

35.7

Male (n = 1350)

5944

82.0 1305 18.0 109

70.8

45

29.2

Limited Contact (n = 1393)

36

969

344

33.5

16.2

43.3

Table 4.2 Retrospective Odds Ratios
History of Concussion
OR
Control
F/M

95% CI

0.940 0.889 - 0.995

One Prior Concussion
OR

95% CI

Two or More Concussions
95% CI

p

4.845

< .05

0.885 0.931 - 0.941 14.987

< .01 1.132 1.023 - 1.253

χ2

p

OR

χ2

χ2

p

5.786

< .05

ADHD

1.915 1.718 - 2.136 141.173

< .01

1.699 1.508 - 1.915 77.393

< .01 1.914 1.602 - 2.286 52.979 < .01

Females

1.931 1.520 - 2.207

41.465

< .01

1.742 1.419 - 2.138 28.890

< .01 1.592 1.165 - 2.176

Males

1.956 1.710 - 2.236

99.201

< .01

1.670 1.442 - 1.934 47.698

< .01 2.120 1.708 - 2.633 48.396 < .01

F/M

0.880 0.704 - 1.100

1.266

37

F/M designates females relative to males.
ADHD odds ratios are relative to control athletes.

0.923 0.723 - 1.178

0.414

0.850 0.589 - 1.226

8.651
0.757

< .01

Table 4.3 Retrospective Odds Ratios by Contact Category
Contact

Limited Contact

OR

95% CI

χ2

p

OR

95% CI

χ2

1.151

1.050 - 1.261

8.961

< .01

0.964

0.853 - 1.088

0.355

ADHD

1.727

1.478 - 2.019

48.104

< .01

1.770

1.404 - 2.232

23.843

F/M

0.959

0.676 - 1.358

0.057

0.820

0.522 - 1.288

0.743

Controls
F/M

Non - Contact

p

< .01

Non - NCAA

38

OR

95% CI

χ2

p

OR

95% CI

χ2

p

1.439

1.208 - 1.715

16.748

< .01

0.878

0.77 - 1.000

3.831

< .05

ADHD

1.720

1.286 - 2.301

13.657

< .01

2.030

1.47 - 2.797

19.455

< .01

F/M

1.974

1.082 - 3.601

5.008

< .05

1.346

0.58 - 3.140

0.474

Controls
F/M

F/M designates females relative to males.
ADHD odds ratios are relative to control athletes.

Table 4.4 Sample Characteristics for Aim 2
Controls
No Cx

ADHD
Cx

No Cx

n

%

n

%

28576

91.8

2546

8.2

1360 89.9 153

10.1

Female (n = 1116)

10645

90.9

1066

9.1

476

90.5

50

9.5

Male (n = 1583)

17931

92.4

1480

7.6

884

89.6 103

10.4

Overall Concussions
(n = 2699)

n

%

Cx
n

%

Incurred Concussion by History
No History (n = 1708)

22617

93.2

1639

6.8

912

93.0

69

7.0

Female (n = 708)

8518

92.5

687

7.5

330

94.0

21

6.0

Male (n = 1000)

14099

93.7

952

6.3

582

92.4

48

7.6

History (n = 991)

5959

86.8

907

13.2

448

84.2

84

15.8

Female (n = 408)

2127

84.9

379

15.1

146

83.4

29

16.6

Male (n = 583)

3832

87.9

528

12.1

302

84.6

55

15.4

Incurred Concussion by Category
Contact (n = 1365)

-

-

1266 92.7

-

-

99

7.3

Female (n = 393)

-

-

368

93.6

-

-

25

6.4

Male (n = 972)

-

-

898

92.4

-

-

74

7.6

Limited Contact (n = 394)

-

-

370

93.9

-

-

24

6.1

Female (n = 279)

-

-

266

95.3

-

-

13

4.7

Male (n = 115)

-

-

104

90.4

-

-

11

9.6

Non-Contact (n = 220)

-

-

209

95.0

-

-

11

5.0

Female (n = 166)

-

-

157

94.6

-

-

9

5.4

Male (n = 54)

-

-

52

96.3

-

-

2

3.7

Non-NCAA (n = 720)

-

-

701

97.4

-

-

19

2.6

Female (n = 278)

-

-

275

98.9

-

-

3

1.1

Male (n = 442)

-

-

426

96.4

-

-

16

3.6

39

Table 4.5 Prospective Relative Risk Ratios
Risk of Concussion
RR
Controls

95% CI

χ2

Risk Without History
p

RR

95% CI

χ2

Risk With History
p

95% CI

χ2

1.194

1.107 - 1.287 21.242 < .01

1.180

1.073 - 1.297 11.73

ADHD

1.236

1.059 - 1.443

7.097

1.041

0.825 - 1.340

0.11

1.195 0.973 - 1.468

2.836

Females

1.044

0.797 - 1.369

0.099

0.802

0.526 - 1.221

1.08

1.096 0.776 - 1.547

0.266

Males

1.369

1.133 - 1.654 10.369 < .01

1.204

0.911 - 1.592

1.69

1.272 0.985 - 1.644

3.316

F/M

0.911

0.661 - 1.255

1.076

0.713 - 1.624

0.92

0.785 0.478 - 1.289

0.823

F/M

0.326
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F/M designates females relative to males.
ADHD risk ratios relative to control athletes.

< .01

< .01

RR

1.249 1.105 - 1.412 12.632

p
< .01

Table 4.6 Prospective Relative Risk Ratios by Contact Category
NCAA Contact

NCAA Limited Contact

Risk

95% CI

χ2

1.040

0.928 - 1.165

ADHD

1.159

F/M

1.025

Controls
F/M

Risk

95% CI

χ2

p

0.454

2.332

1.94 - 3.080

60.241

< .01

0.959 - 1.401

0.299

1.178

0.790 - 1.756

0.643

0.67 - 1.559

0.014

1.407

0.647 - 3.058

0.750

p

NCAA Non-Contact

Non-NCAA
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Risk

95% CI

χ2

p

Risk

95% CI

χ2

p

1.546

1.140 - 2.103

7.873

< .01

2.199

1.905 - 2.539

118.085

< .01

ADHD

0.931

0.514 - 1.687

0.055

1.396

0.907 - 2.150

2.252

F/M

3.226

0.710 - 14.652

*

1.031

0.322 - 3.308

*

Controls
F/M

0.09

F/M designates females relative to males. All ADHD risk ratios relative to control athletes.
* Indicates Fisher’s exact p-value is reported.

0.588

Unique athletes who experienced a single concussion during the study with complete ImPACT data at
Baseline, 24-48hr post injury and at RTP
(pre-exclusion n = 1,227)
Excluded (n = 358)
• 6 reported moderate-to-severe TBI
• 38 reported specific learning disorder, memory disorders, or psychiatric disorder (Bipolar,
schizophrenia)
• 314 missing data for either injury or demographic data
Unique Eligible Athletes (n = 869)
Controls (pre-exclusion n = 771)
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Excluded Controls (n = 155)
• 46 failed a year of high
school.
• 75 taking medications
with known cognitive
effects.
• 34 significant outliers

ADHD+Rx (n = 46)
Excluded ADHD+Rx (n = 10)
• 6 Missing Rx name
• 1 Non-stimulant Rx
• 3 Significant Outlier on
more than one data point

ADHD_uRx (n = 52)
Excluded ADHD_uRx (n = 14)
• 8 Reported no Rx but
listed a stimulant Rx
name.
• 6 Significant outliers on
more than one data point

Unique Athletes Eligible for Matching Criteria (n = 690)
Double Matched Controls
(n = 140)

Matched ADHD+Rx
(n = 35)

Figure 4.2 Selection Criteria for Specific Aim 3

Matched ADHD_uRx
(n = 35)

Table 4.7 Sample Characteristics for Aim 3 (Mean ± S.D.)
Controls

ADHD+Rx

ADHD_uRx

Total Sample

140

35

35

Male

100

26

24

Female

40

9

11

Characteristics

F

p

η2
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BMI

24.6 ± 4.6

24.7 ± 4.2

26.2 ± 2.9 *

4.001

.02

.038

Age at Baseline

18.9 ± 1.5

19.2 ± 1.3

19.1 ± 1.4

1.018

.363

.010

Age at Injury

20.4 ± 1.6

20.9 ± 1.6

21.1 ± 1.

1.586

.211

.040

Years of Sport Participation

10.1 ± 3.5

10.9 ± 2.9

10.4 ± 4.0

.683

.506

.008

Concussion History

50 (35.7%)

10 (28.6%)

21 (60%) **

5.353

.005

.049

One

39 (27.9%)

8 (22.9%)

15 (42.9%)

Two or more

11 (7.9%)

2 (5.7%)

6 (17.1%)

15.6 ± 2.8

15.8 ± 1.2

15.0 ± 2.6

.827

.441

.021

.335

.011

Age at first concussion

Post-Concussion (Days from injury to time point)
Injury reported

1.2 ± 2.2

1.7 ± 2.6

1.8 ± 4.1

1.099

Symptom resolution

5.4 ± 3.5

6.2 ± 4.9

9.2 ± 6.9 **

9.452

* Significant from controls only; ** Significant from all other groups

< .001 .084

Table 4.8 ImPACT Scores (Mean ± S.D.)
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Control
ADHD+Rx
Baseline 4.686 ± 0.342
6.486 ± 0.684
Impulse Control
24 - 48hr 6.071 ± 0.473
9.400 ± 0.946*
Composite
uRTP
5.771 ± 0.429
9.057 ± 0.858**
Baseline 0.584 ± 0.007
0.581 ± 0.014
Reaction Time
24 - 48hr 0.606 ± 0.009
0.636 ± 0.018
(seconds)
uRTP
0.567 ± 0.007
0.565 ± 0.014
Baseline 7.257 ± 0.786
8.200 ± 1.571
Total Symptom
24 - 48hr 18.507 ± 1.588
23.486 ± 3.176
Score
uRTP
0.629 ± 0.151** 1.429 ± 0.302
Baseline 86.393 ± 0.897
84.571 ± 1.793
Verbal Memory
24 - 48hr 87.179 ± 1.115** 80.343 ± 2.229
Composite
uRTP
92.029 ± 0.702
91.400 ± 1.403
Baseline 78.364 ± 1.231
75.114 ± 2.463
Visual Memory
24 - 48hr 75.300 ± 1.233
71.514 ± 2.466
Composite
uRTP
79.036 ± 1.174
76.200 ± 2.348
Baseline 42.602 ± 0.591
41.871 ± 1.181
Visual Motor Speed
24 - 48hr 42.156 ± 0.654
39.331 ± 1.307
Composite
uRTP
44.974 ± 0.566
42.813 ± 1.131
Baseline 0.337 ± 0.012
0.313 ± 0.025
Cognitive Efficiency
24 - 48hr 0.367 ± 0.012
0.313 ± 0.025
Index
uRTP
0.421 ± 0.013
0.416 ± 0.026
* Significant from controls only, ** Significant from all other groups

F
p
η2
ADHD_uRx
7.343 ± 0.684*
7.463 0.001 0.067
8.000 ± 0.946
5.689 0.004 0.052
5.829 ± 0.858
6.074 0.003 0.055
0.631 ± 0.014*
4.670 0.010 0.043
0.683 ± 0.018*
7.403 0.001 0.067
0.608 ± 0.014**
3.817 0.024 0.036
7.543 ± 1.571
0.146 0.865 0.001
22.771 ± 3.176
1.424 0.243 0.014
1.486 ± 0.322
3.230 0.042 0.030
83.886 ± 1.793
3.010 0.051 0.028
78.743 ± 2.229
7.951 0.000 0.071
87.857 ± 1.403*
3.545 0.031 0.033
71.971 ± 2.463
2.962 0.054 0.028
69.514 ± 2.466*
2.675 0.071 0.025
71.514 ± 2.348*
4.239 0.016 0.039
38.350 ± 1.181*
5.184 0.006 0.048
35.248 ± 1.307** 11.673 0.000 0.101
41.877 ± 1.131*
3.769 0.025 0.035
0.286 ± 0.025
1.816 0.165 0.017
0.281 ± 0.025*
5.666 0.004 0.052
0.351 ± 0.026
3.010 0.051 0.028

CHAPTER 5: DISCUSSION
The primary aims of this study were to cross-sectionally and prospectively
investigate the influence of ADHD on the 1) odds of concussion history, the 2) relative risk
of incurring a concussion, and to 3) determine whether medication status influences
recovery among college athletes with ADHD.
Specific Aims 1 & 2
Consistent with our hypotheses, we observed that both male and female athletes
with self-reported diagnosis of ADHD had significantly greater odds of single and multiple
concussions than controls, replicating prior results.26 Additionally, we observed the same
pattern when stratifying by sport-contact category type, athletes with ADHD had
significantly greater odds of single and multiple concussions than controls for contact,
limited contact, non-contact, and non-NCAA categories. Interestingly, we observed that
females with ADHD in the non-contact category had significantly greater odds of
concussion than males with ADHD in the non-contact category. However, the reason
behind this divergence is unclear. Thus, further investigation is needed regarding the
confluence of sport-contact type and sex on concussion history.
Consistent with our hypotheses, we prospectively observed that all athletes with
ADHD had greater risk for incurring a concussion during the study period. However,
females with ADHD did not have increased risk for concussion despite having increased
odds, relative to female controls. Based on these findings, a dissociation appears to exist
between females and males with ADHD regarding the confluence of ADHD and prior
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concussion history on concussion risk, relative to sex specific controls. There are several
possible explanations for these findings, such as objective sex differences or varying
degrees of aggressive styles of play between males and females. Additionally, it is possible
that various sports males and females participate in have various levels of “contact” and
differing rule sets, for example female ice hockey is a “no checking” sport, whereas male
ice hockey allows full contact. Owing to the lack of comprehensive physiological data, any
causally mechanistic discussion is speculative, however we will highlight features that are
believed to contribute to our findings.
Specific Aim 3
Baseline
We hypothesized a priori differences between medicated and unmedicated athletes
in terms of clinical symptoms and cognition. We observed that unmedicated athletes with
ADHD performed worse on measures of impulse control, reaction time, and visual motor
speed. These findings are consistent with previous findings from ADHD and concussion
studies50,

57-61

. However, while some results are statistically significant, we feel it is

important to mention that this may not be a clinically meaningful difference (i.e., reaction
time differences between 567 and 608ms).
24 – 48 hours post injury
In accordance with our hypotheses, we observed group differences at 24-48 hours
post-injury while using baseline values as covariate. The unmedicated ADHD group
performed worse than controls, but not the medicated ADHD group, for reaction time,
visual memory, and cognitive efficiency. However, the unmedicated ADHD group
performed worse than both medicated ADHD and controls for visual motor speed.
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Interestingly, the medicated ADHD group performed worse than controls, but not
unmedicated ADHD, for impulse control, suggesting a reemergence of self-regulatory
difficulties for medicated ADHD.
Unrestricted Return-to-play
As hypothesized, there were some differences at uRTP between groups. The
unmedicated ADHD group performed worse for reaction time than both controls and
medicated ADHD. Controls also reported fewer total symptoms than either medicated or
unmedicated. Additionally, the unmedicated ADHD group performed worse than
controls, but not medicated ADHD for verbal memory, visual memory, and visual motor
speed.
The unmedicated ADHD group reported greater duration of symptoms than either
controls or medicated ADHD.
Interestingly, the three most closely related composites are impulse control,
reaction time, and visual motor speed. For example, delayed reaction time and response
speed suggest inefficient inhibition of a response or movement based on rule sets or
decision making. Accordingly, there were differences between the medicated and
unmedicated ADHD group, but no differences between the medicated ADHD group and
controls for impulse control, reaction speed, and visual motor speed. This suggests that
medications are working as expected given their abilities to regulate impulse control in
those with ADHD. These findings appear to replicate previously reported effects of these
stimulant medications on neurocognitive test performance.59, 63, 65-68 Acknowledging these
preexisting differences reinforces the potential importance for ADHD medicated and
unmedicated specific normative data for use when pre-season baseline testing is not
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available or not a viable option. However, the only available normative data is non-ADHD
specific as it includes any learning problems, special education needs, and is from 2003
using a limited sample size (total n = 256). Thus, the individual baseline analysis and
inclusion as a covariate is an important feature of our study.
Potential Mechanisms
While this investigation did not employ any physiological measures, it is still
important to mention mechanisms by which the presence of ADHD contribute to
concussion (aims 1 & 2) as well as how ADHD medication may influence concussion
symptoms (aim 3).
That all athletes with ADHD had greater odds for multiple prior concussions poses
interesting questions regarding mechanisms (aims 1 & 2). Currently, it is not feasible to
ascertain the underlying causative mechanisms for increased susceptibility for recurrent
concussions, however we can speculate based on existing knowledge. First, it is widely
acknowledged that a history of concussion is a probable risk factor for recurrent
concussion20, 22, 79, 118, 120. It is possible that structural and physiological alterations often
observed in athletes with ADHD, such as reductions in axonal integrity, glucose
metabolism, cerebral blood flow, and catecholamine levels, render these athletes more
susceptible. Thus the “threshold at which concussion occurs” (i.e., velocity, impact ratings
etc.) may be lessened in these athletes resulting in a greater incidence and risk for
concussive injuries; however, to our knowledge no physiological or kinematic data exists
in athletes with ADHD. There is some data suggesting there are motor control alterations
which linger for weeks to years after concussion

258-262

. Taken in consideration with

reported motor control deficits commonly reported in ADHD, it is also possible that
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increased rate of concussions in athletes with ADHD is partially a result of pre-injury motor
deficits being exacerbated by concussion.
Although the physiology is likely complex, neuro-behavioral mechanism may be
involved in the observed increased occurrence of concussion. ADHD is widely
acknowledged to be a disorder of executive functions, particularly those of inhibition (i.e.,
impulse control) and attentional focus. Any deficits in inhibition and/or attentional focus
represent a concern for athletes in sport environments.
Inhibition deficits in athletes may manifest as unnecessary risk taking, ignoring the
potential outcomes of negative or dangerous actions, or heightened distractibility. Athletes
with ADHD, due to lack of inhibitory control in the moment, may be placing themselves
in potentially dangerous situations, such as head-to-head contact when unintended. Also,
inhibition may result in the inability to filter out irrelevant information, resulting in
distraction and a potentially hazardous situation. These situations may contribute to the
observed increased prevalence of concussions among athletes with ADHD.
Similarly, any failure to attend to surrounding features, including the position,
and/or intention of an opponent during active play could result in an impact related blow.
If an athlete has ADHD, they may not be attending to the spatial position of these cues and
place themselves at risk for concussive impacts or fall. Further, attending to a non-relevant
cue in the environment may act as a distractor from potential hazards. Thus, behavioral
lapses in attention to environment cues may also contribute to increased concussion
occurrence in athletes with ADHD. However, this level of inattention during sport is most
likely to be observed in children or adolescents and not observed as often in elite-level
athletes as those most often seen in college.
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Current evidence suggests that symptom severity is correlated with the degree to
which metabolism is impaired 17, 98, 133, 142, 144. Accordingly, the deficits in neurocognitive
performance observed in those with ADHD may be partly explained by a detrimental
interaction between impairments inherent to ADHD and impairments induced by
concussion. A possible consideration is the direct influence of stimulant medications, both
AMPH (amphetamine) and MPH (methylphenidate) result in enhanced availability and/or
activity of dopamine and, by extension, norepinephrine. Each of these neurotransmitters
acts on key areas of the brain, particularly the areas involved in vigilance, impulse control,
fine motor control, coordination, and reaction time263,

264

. Enhancing neurotransmitter

signaling by using these medications may lead to improved metabolic activity, such as
relatively normalizing glucose metabolism, leading to increased ATP production by the
mitochondria, mitigating some of the acute effects of the neurometabolic cascade following
concussion.
Healthy mitochondrial function includes a dynamic lifecycle called mitochondrial
dynamics and is regulated by diverse complex mechanisms. However, this cycle can be
simplified into 1) fusing with other mitochondria (fusion) and 2) dividing into separate
mitochondria (fission). Fusion is a beneficial mechanism for consolidating multiple
damaged organelles into a single organelle, and the subsequent fission into a healthy
organelle and an organelle marked for autophagy. Mitochondrial dynamics are vital for
axonal transport (i.e., anterograde and retrograde) to neuronal regions with the greatest
energy requirements and is thought to be regulated by both the local metabolic state as well
as the distribution of other mitochondria265. Mitochondria localized to synapses are
necessary to manage the energetic requirements of ATP-depended processes and regulate
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Ca2+ concentrations during periods of intense activation266-268. Additionally, this cycle is a
particularly important facilitator of apoptosis during periods of increased cellular stress,
such as the period following concussion.
In the concussion literature, several studies have reported that following an initial
injury there exists a period following injury during which mitochondrial fission and
autophagy exceeds mitochondrial fusion269-273. This lag time appears to reflect the acute
bioenergetic impairments that accompany concussion. Given the importance of
mitochondrial function to homeostasis and meeting bioenergetic needs, this suggests that
there is a period during which the neuron may be biochemically, metabolically, and perhaps
even structurally attenuated due to mitochondrial dysfunction274. Following a concussion
there is increased demand for ATP in order restore ionic concentrations15,

16, 98

. This

increased demand requires excessive ATP production which is accompanied by increased
production of reactive oxygen species (ROS), a natural byproduct. However, if the quantity
of oxidants exceeds the buffering abilities of cellular antioxidants, then ROS toxicity may
occur. ROS toxicity impairs glucose uptake and metabolism275, cellular membrane
damage, cause genetic mutations, and/or result in apoptosis

276

, all of which may be

collectively referred to as oxidative stress (OxS).
The healthy brain may be particularly vulnerable to OxS due to increased energy
demands and therefore dependency on mitochondria, thus with various injuries or disorders
increased OxS may be increasingly detrimental. Indeed, OxS has been implicated in
neurodegenerative diseases such as Alzheimer’s disease277,
amyotrophic lateral sclerosis280,

281

278

, Parkinson’s disease279,

, acute neurodegeneration resulting from cerebral

ischemia,282 and traumatic brain injury283-285. Several studies have reported that individuals
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with ADHD have abnormally elevated levels of oxidative stress 286-292. Furthermore, it has
been demonstrated that in ADHD, absent history of brain injury, there is an insufficient
antioxidant response to increases in ROS, which activates intracellular signaling thereby
modulating glucose uptake and metabolism and resulting in bioenergetic impairment.
Collectively, it is plausible that increased ROS production may be a hallmark of
mitochondrial dysfunction in ADHD and following concussion

293, 294

. While evidence

regarding mitochondrial bioenergetics in ADHD pathogenesis is limited, there is some
evidence that OxS is a characteristic in ADHD295.
In summary, mitochondria help regulate Ca2+ concentrations and produce ATP via
cellular respiration using glucose and oxygen. In individuals with ADHD there are existing
glucose deficits, reduced cerebral blood flow resulting in reduced oxygen availability, and
increased OxS, particularly when not taking medication296. Incurring a concussion
exacerbates these deficits via the neurometabolic cascade and subsequent energy deficits
as previously discussed. As seen in nearly all measures, individuals with medicated ADHD
appeared to perform better than unmedicated ADHD. Physiologically, it is therefore
plausible that psychostimulant medications mitigate some of these underlying ADHD
specific deficits. For example, MPH not only regulates catecholamine uptake but also
stimulates glycolysis and increases creatine kinase activity297 which may further help to
mitigate energy deficiencies and therefore reduce suspected physiological underpinnings
of ADHD. Indeed, early in the concussion treatment literature physicians were prescribing
psychostimulants to treat concussion symptoms298, however that practice has been called
into question as more data on concussion is gathered.
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The effects of psychostimulant medications are largely noticeable in the prefrontal
cortex, striatum, and nucleus accumbens, areas closely associated with cognitive functions.
Thus, these medications serve to enhance metabolic activity, neurotransmitter availability
and activity, resulting in a net increase in cognitive functions. Further evidence suggesting
these medications (i.e., MPH and AMPH) may enhance cognitive processes is reflected in
the few studies demonstrating that athletes without a neurodevelopmental disorder taking
these medications perform better on cognitive tasks than when not taking these medications
(i.e., within subjects) absent concussion65. Collectively, this may be a possible explanation
why the medicated groups’ cognitive scores were more comparable to controls than to the
unmedicated groups following concussion.
Limitations
These investigations have several methodological limitations. For Aims 1 & 2 we
were unable to include exposure rates in our analysis. Of note, this sample contains sports
in which there were disproportionate representations of a single sex and is therefore
possible some findings are subject to sample bias. For Aim 1, the cross-sectional nature of
retrospective self-reported ADHD diagnoses and prior concussions history prevents any
determinations of temporality for concussion odds. However, since most ADHD diagnoses
are made during early childhood it is likely they received a diagnosis before sustaining a
concussion, although secondary ADHD following a moderate or severe brain injury has
been reported previously.49 Additionally, diagnosis of ADHD was self-reported, therefore
it is possible that some athletes did not report their diagnosis due to concern of stigma
associated with ADHD. Furthermore, we did not exclude athletes with an IEP or 504-plan
as there are many ways in which these may be provided to students without ADHD.
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However, we excluded all participants who did not report ADHD but repeated a grade to
control for this possibility. Furthermore, the rates of ADHD are relatively consistent with
previous studies of collegiate athletes.30, 50, 55
For Aims 1 & 2 we included athletes who did and did not take psycho-stimulant
medications for their diagnoses to accurately represent the overall body of athletes with
NDs. It is possible that differences exist between medicated and un-medicated athletes, or
potential changes to medications during the study could influence injury odds and risk.
However, there were no statistically significant differences in an exploratory analysis
examining odds and risk by psycho-stimulant medication status within the ADHD group.
For aim 3 we feel it is important to note that impulsivity is often considered a
marker of validity, rather than a cognitive-behavioral indices, additional the cognitive
efficiency index has been removed from the ImPACT output as of version 4.0. We included
self-report diagnosis of ADHD, as well as self-reported psychostimulant medications.
While it is plausible that athletes or others involved were unaware of what constitutes a
psychostimulant, we excluded all medications other than verifiable formulations of
amphetamine and methylphenidate (i.e., Vyvanse, Ritalin, etc.). Additionally, we excluded
athletes taking a combination of stimulant and non-stimulant medications. Thus, our
sample may be biased towards higher performers in that we excluded mediations for
anxiety and depression, which are very common among athletes, individuals with ADHD,
and following concussion.299 Furthermore, we have no way of knowing if the athletes were
consistent in their medication usage, dosage, or whether they continued taking their
medications post-injury. Lastly, many psychostimulant medications are used to treat
multiple conditions and not just ADHD, for example most psychostimulants may be used
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to treat narcolepsy. However, we only included medicated individuals reporting ADHD
which minimizes the likelihood of a prescription based on unknown or unreported
diagnoses. Admittedly, we were unable to account for athletes who surreptitiously used
these medications without a diagnosis or without a prescription.
Conclusion
In summary, this is the largest study to date to examine the influences of ADHD on
concussion and concussion outcomes. Our findings for aims 1 and 2 further the existing
literature by detailing the confluence of sex, neurodevelopment, and sport-contact type
with concussion history and risk for incurring a future concussion. Our findings for aim 3
suggest there are some differences between athletes with ADHD control athletes,
particularly regarding medication status. Athletes with medicated ADHD appear to have
normalized baseline performance relative to unmedicated athletes with ADHD.
To our knowledge, these are the first findings of its kind and reinforces both the
need to further examine the differential factors that predispose male and female athletes to
concussion and the need for longitudinal investigation of concussion recovery, particularly
regarding medications in athletes with ADHD. It is our hope that these results aid sport
medical teams in determining “at-risk” athletes who may be more susceptible for
concussive injury and potentially poorer injury outcomes.
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